We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Molecular Prognostic Biomarker Found for CNS Lymphoma

By LabMedica International staff writers
Posted on 24 Jan 2019
Primary central nervous system lymphoma (PCNSL), a rare subgroup of diffuse large B-cell lymphoma (DLBCL) arising in the central nervous system (CNS), is an aggressive malignant variant of nodal non-Hodgkin lymphoma (NHL). More...
PCNSLs account for 3% of all primary CNS tumors and 1% of NHLs in adults.

MicroRNAs (miRNAs) are small noncoding regulatory RNAs consisting of approximately 20-mer nucleotides, that inhibit gene function through suppression of translation of target genes. Dysregulation of miRNA expression and RNA interference (RNAi) mechanism are related to tumor malignancy in chronic lymphocytic leukemia and acute lymphoblastic leukemia.

Scientists at Kyoto Prefectural University of Medicine (Kyoto, Japan) and their colleagues deciphered the miRNA signature through analysis between the expression patterns of miRNAs and their correlation to the prognosis in 27 PCNSL specimens. They first selected 16 miRNA candidates from the 847 miRNAs detected using microarray technique. Then based on principal component analysis (PCA) after Random forest analysis and clustering analysis, they determined that miR-181b, miR-30d, and miR-93 constituted a miRNA signature in PCNSL.

Total RNA was extracted from approximately 100 mg of each tumor tissue and the quality of the extracted RNA was verified with a Bioanalyzer System using RNA Pico Chips. The RNA was amplified twice and used for hybridization with Affymetrix GeneChip miRNA Array, comprising of 30,424 probes. After hybridization, the array chips for target detection were processed, washed, and stained using the Fluidics Station 450. The High-Resolution Microarray Scanner 3000 was used for scanning the signal, and GCOS Workstation Version 1.3 was employed for image-quality analysis.

The team considered the prognostic clues provided by the 16-miRNA gene set, and by a subset of three quantitative PCR-validated miRNAs found by Random forest analysis and clustering analyses: miR-30d, miR-93, and miR-181b. The expression profiles for miRNAs from both signatures could successfully separate PCNSL patients with poor or more favorable overall survival rates. These miRNAs have been implicated in processes ranging from new blood vessel formation to cell migration, proliferation, and immune function, the team noted, and were highly expressed in almost half the PCNSLs tested. The study was published on January 7, 2019, in the journal Public Library of Science ONE.

Related Links:
Kyoto Prefectural University of Medicine


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.